www.fdanews.com/articles/175936-azs-brilinta-falls-short-in-aspirin-comparison
AZ’s Brilinta Falls Short in Aspirin Comparison
March 29, 2016
AstraZeneca’s heart drug Brilinta fared no better than aspirin in preventing vascular events in stroke patients, according to study data unveiled last week.
The SOCRATES trial compared Brilinta 90 mg twice daily to once-daily aspirin 100 mg. The primary endpoint evaluated whether Brilinta prevented major vascular events in patients 40 or older with an acute ischaemic stroke.
AstraZeneca will continue trials to assess Brilinta’s efficacy in treating other high-risk populations.